Benralizumab 100 mg vs placebo
Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyRate ratio 0.88 [0.78, 1]2 studies · 1512 participantsModerate